In the original version of this article (1), Fig. 1 was incomplete and the "Methods" sections of both the abstract and the article stated that patients received drugs thrice weekly instead of every three weeks. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced non-squamous non–small-cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–95.
ASJC Scopus subject areas
- Cancer Research